Bal Pharma

Which are the latest news on Bal Pharma?

How big is Bal Pharma?

As of 10th June, Bal Pharma Ltd has a market capitalization of 140.00 Cr, with net sales of 311.66 Cr and a net profit of 6.28 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Bal Pharma Ltd has a market capitalization of 140.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 311.66 Cr, while the sum of Net Profit for the same period is 6.28 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 77.42 Cr, and Total Assets amount to 335.28 Cr.

Why is Bal Pharma Ltd falling/rising?

As of 10-Jun, Bal Pharma Ltd's stock price is at 86.06, down 1.17%. This decline is due to underperformance compared to the benchmark Sensex, reduced investor participation, and a negative yearly performance, despite some positive trends over the past month and year-to-date.

As of 10-Jun, Bal Pharma Ltd's stock price is currently at 86.06, reflecting a decrease of 1.02, or 1.17%. This decline can be attributed to several factors. Over the past week, the stock has underperformed, showing a decline of 1.74%, while the benchmark Sensex has only decreased by 0.49%. Additionally, the stock has experienced a significant drop in investor participation, with delivery volume falling by 26.76% compared to the 5-day average. <BR><BR>Despite some positive performance over the longer term, such as a 5.96% increase over the past month and a 17.49% rise year-to-date, the stock's performance over the past year has been negative, with a decline of 14.62%. Furthermore, while the stock is currently above its 20-day, 50-day, 100-day, and 200-day moving averages, it is below its 5-day moving average, indicating a short-term weakness. These combined factors contribute to the current downward trend in Bal Pharma Ltd's stock price.

What does Bal Pharma do?

Bal Pharma Ltd is a micro-cap pharmaceutical and biotechnology company focused on manufacturing pharmaceutical formulations, with a market cap of INR 140 Cr and reported net sales of 84 Cr and net profit of 4 Cr for the quarter ending March 2026. The company was incorporated in 1987 and operates from Bangalore, India.

Overview: <BR>Bal Pharma Ltd is a pharmaceutical and biotechnology company operating in the micro-cap market segment, focusing on the manufacturing of pharmaceutical formulations.<BR><BR>History: <BR>Bal Pharma Ltd was incorporated as a private limited company in May 1987. In March 1990, the company took over a pharmaceutical products manufacturing unit in Bangalore. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 84 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 140 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.37% <BR>Debt-Equity: 1.83 <BR>Return on Equity: 7.64% <BR>Price to Book: 1.69<BR><BR>Contact Details: <BR>Address: 21 & 22 Bommasandra Indl Area, Hosur Road Bangalore Karnataka : 560092 <BR>Email: secretarial@balpharma.com/info@balp <BR>Website: http://www.balpharma.com

Should I buy, sell or hold Bal Pharma Ltd?

Are Bal Pharma Ltd latest results good or bad?

Bal Pharma Ltd's latest results are mixed; while net profit rose 101.69% quarter-on-quarter to ₹3.59 crore, it declined 33.89% year-on-year, and revenue fell 4.12% from the previous quarter despite a 2.69% year-on-year increase. Investors should be cautious due to underlying concerns about sustainability and low returns on equity.

Bal Pharma Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹3.59 crore, which is a significant improvement of 101.69% quarter-on-quarter. However, this figure represents a decline of 33.89% compared to the same quarter last year. <BR><BR>Revenue for the same period was ₹84.08 crore, which is a decrease of 4.12% from the previous quarter but shows a modest increase of 2.69% year-on-year. While the operating margin improved to 12.57%, the overall revenue decline raises concerns about the company's ability to maintain growth.<BR><BR>The substantial increase in net profit is largely attributed to improved operational efficiency and favorable tax adjustments, but the reliance on these factors for profitability may indicate underlying issues with sustainability. Additionally, Bal Pharma's return on equity and capital employed remain low, suggesting that the company is not generating adequate returns relative to its equity and capital investments.<BR><BR>Overall, while there are positive aspects, such as margin expansion and a sequential recovery in profit, the year-on-year declines in both profit and revenue, along with high leverage and weak operational metrics, suggest that the results are not entirely favorable. Investors should approach with caution, given the mixed signals from the latest financial performance.

When is the next results date for Bal Pharma Ltd?

The next results date for Bal Pharma Ltd is 27 May 2026.

The next results date for Bal Pharma Ltd is scheduled for 27 May 2026.

Is Bal Pharma overvalued or undervalued?

As of November 14, 2025, Bal Pharma is considered an attractive investment due to its undervalued financial metrics, including a PE Ratio of 18.76 and an EV to EBITDA of 10.07, especially when compared to more expensive peers like Sun Pharma and Divi's Lab.

As of 14 November 2025, Bal Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 18.76, an EV to EBITDA of 10.07, and a Price to Book Value of 1.63, which suggest a favorable valuation relative to its earnings and asset base.<BR><BR>In comparison to its peers, Bal Pharma's PE Ratio is significantly lower than Sun Pharma's 36.49 and Divi's Lab's 69.65, both of which are categorized as expensive. Additionally, its EV to EBITDA is more favorable than that of Torrent Pharma, which stands at 33.11. Despite recent underperformance compared to the Sensex, with a year-to-date return of -34.27% versus the Sensex's 8.22%, Bal Pharma's current valuation metrics indicate it remains an attractive investment opportunity within the pharmaceuticals and biotechnology sector.

How has been the historical performance of Bal Pharma?

Bal Pharma's historical performance shows a decline in net sales from 339.22 Cr in March 2024 to 303.08 Cr in March 2025, with operating profit decreasing from 33.60 Cr to 31.76 Cr and profit before tax falling from 9.05 Cr to 5.14 Cr, while profit after tax remained stable. Total liabilities increased to 335.28 Cr, indicating rising debt levels, and cash flow from operating activities decreased to 20.00 Cr, resulting in a net cash outflow of 2.00 Cr.

Answer:<BR>The historical performance of Bal Pharma shows a fluctuating trend in net sales and profits over the years, with a net sales figure of 303.08 Cr in March 2025, down from 339.22 Cr in March 2024. The total operating income also reflects this decline, with a decrease from 339.22 Cr in March 2024 to 303.08 Cr in March 2025. Operating profit (PBDIT) slightly decreased to 31.76 Cr in March 2025 from 33.60 Cr in March 2024, while profit before tax fell to 5.14 Cr from 9.05 Cr in the previous year. However, profit after tax remained relatively stable at 7.24 Cr in March 2025 compared to 7.45 Cr in March 2024. The company's total liabilities increased to 335.28 Cr in March 2025 from 319.84 Cr in March 2024, indicating a rise in debt levels, which reached 150.38 Cr. Cash flow from operating activities decreased to 20.00 Cr in March 2025 from 22.00 Cr in March 2024, contributing to a net cash outflow of 2.00 Cr in March 2025.<BR><BR>Breakdown:<BR>Bal Pharma's financial performance over the years indicates a mixed trend in key metrics. The net sales peaked at 339.22 Cr in March 2024 but dropped to 303.08 Cr in March 2025. Operating profit (PBDIT) followed a similar pattern, decreasing from 33.60 Cr to 31.76 Cr. Profit before tax also saw a decline from 9.05 Cr to 5.14 Cr, while profit after tax remained relatively stable, showing a slight decrease from 7.45 Cr to 7.24 Cr. The company's total liabilities increased to 335.28 Cr, driven by a rise in total debt to 150.38 Cr. Cash flow from operating activities decreased to 20.00 Cr, contributing to a net cash outflow of 2.00 Cr in March 2025. Overall, while Bal Pharma has shown resilience in maintaining profit levels, the decline in sales and operating profit raises concerns about its future performance.

Who are in the management team of Bal Pharma?

As of March 2023, the management team of Bal Pharma includes Shailesh Siroya (Managing Director), Himesh Virupakshaya (Executive Director), Kotian Chittananda Damodar (Whole-time Director), and several Independent Directors: C V Srinivas, H S Venkatesh, Nicola Neeladri, and Jatish Sheth, along with Abdul Basith (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2023, the management team of Bal Pharma includes the following individuals:<BR><BR>1. Shailesh Siroya - Managing Director<BR>2. C V Srinivas - Independent Director<BR>3. Himesh Virupakshaya - Executive Director<BR>4. H S Venkatesh - Independent Director<BR>5. Nicola Neeladri - Independent Director<BR>6. Jatish Sheth - Independent Director<BR>7. Kotian Chittananda Damodar - Whole-time Director<BR>8. Abdul Basith - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What is the technical trend for Bal Pharma?

As of May 29, 2025, Bal Pharma's technical trend is mildly bearish, with mixed signals from MACD and KST across different time frames, while daily moving averages reinforce a cautious outlook.

As of 29 May 2025, the technical trend for Bal Pharma has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend, suggesting mixed signals across time frames. The daily moving averages are mildly bearish, reinforcing the overall cautious outlook. Bollinger Bands on the weekly chart are bullish, but the monthly perspective is mildly bearish. The KST also reflects a mildly bullish weekly trend but is bearish on the monthly. There are no clear signals from the RSI, Dow Theory, or OBV, indicating a lack of strong momentum in either direction. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from the MACD and KST.

Who are the top shareholders of the Bal Pharma?

The top shareholders of Bal Pharma include promoter Shailesh Siroya with 17.24%, individual investors with 32.49%, and public shareholder Prakash Chandra Jain at 3.65%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Bal Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Shailesh Siroya, who owns 17.24% of the company. Additionally, individual investors collectively hold 32.49% of the shares. In terms of public shareholders, Prakash Chandra Jain is the highest with a holding of 3.65%. There are also three foreign institutional investors (FIIs) that hold a total of 0.14% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Has Bal Pharma declared dividend?

Bal Pharma Ltd has declared a 12% dividend, with an ex-date of September 17, 2024. While recent total returns have shown volatility, the company has demonstrated positive long-term performance, particularly with a total return of 154.7% over the past five years.

Bal Pharma Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 1.2%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -18.37%, with a dividend return of 0%, resulting in a total return of -18.37%.<BR><BR>Over the past year, the price return was -9.65%, the dividend return was 0.99%, leading to a total return of -8.66%.<BR><BR>In the 2-year period, the price return was 13.72%, the dividend return was 2.46%, culminating in a total return of 16.18%.<BR><BR>For the 3-year period, the price return was 1.86%, with a dividend return of 3.57%, resulting in a total return of 5.43%.<BR><BR>In the last 4 years, the price return was 1.25%, the dividend return was 4.27%, which gave a total return of 5.52%.<BR><BR>Finally, over the past 5 years, the price return was 144.7%, with a dividend return of 10.00%, leading to a total return of 154.7%.<BR><BR>Overall, Bal Pharma has declared a dividend, and while the recent total returns show some volatility, particularly in the short term, the longer-term returns indicate a positive trend, especially over the 5-year period.

Who are the peers of the Bal Pharma?

Bal Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, Aarey Drugs, Denis Chem Lab, Tyche Industries, and Quest. While Sun Pharma and Cipla show excellent growth and management, Bal Pharma has average management risk and below-average growth and capital structure.

Peers: The peers of Bal Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, Aarey Drugs, Denis Chem Lab, Tyche Industries, and Quest.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, and Tyche Industries, while Average management risk is found at Bal Pharma, Aarey Drugs, and Denis Chem Lab. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Bal Pharma, Torrent Pharma, and Aarey Drugs exhibit good growth. Below average growth is noted for Divi's Lab., Smruthi Organic, Denis Chem Lab, and Tyche Industries. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Smruthi Organic, and Tyche Industries, while Bal Pharma, Aarey Drugs, and Denis Chem Lab have below average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Denis Chem Lab has the lowest at -38.43%. Bal Pharma's 1-year return is -13.63%, which is lower than both. Additionally, the six-month return is negative for Denis Chem Lab, Tyche Industries, and Bal Pharma.